- Home
- PCF vs CGTX Comparison
PCF vs CGTX Comparison
Compare PCF & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PCF | CGTX |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 113.0M | 94.5M |
| IPO Year | 1994 | 2021 |
Fundamental Metrics
Financial Performance| Metric | PCF | CGTX |
|---|---|---|
| Price | $5.62 | $0.87 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $3.33 |
| AVG Volume (30 Days) | 96.0K | ★ 1.3M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.36 | $0.22 |
| 52 Week High | $6.52 | $3.83 |
Technical Indicators
Market Signals| Indicator | PCF | CGTX |
|---|---|---|
| Relative Strength Index (RSI) | 47.28 | 41.69 |
| Support Level | $5.36 | $0.56 |
| Resistance Level | $6.14 | $0.87 |
| Average True Range (ATR) | 0.08 | 0.13 |
| MACD | 0.03 | -0.02 |
| Stochastic Oscillator | 81.82 | 45.38 |
Price Performance
Historical ComparisonAbout PCF High Income Securities Fund
High Income Securities Fund is a closed-end management investment company. Its primary objective is to provide high current income and capital appreciation is the secondary objective. The Fund pursues its objective mainly by investing in both convertible bonds and convertible preferred stocks. The Fund also invests significantly in high-yielding non-convertible securities with the potential for capital appreciation.
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.